India, June 3 -- Shares of Kiora Pharmaceuticals, Inc. (KPRX) gained over 24% on Tuesday morning after the company announced it has granted Senju Pharmaceutical Co., Ltd. an exclusive option to exercise rights to an exclusive development and commercialization agreement for KIO-301 for the treatment of ophthalmic diseases.
KPRX is currently trading at $3.5400, up $0.6900 or 24.2105%, on a large volume of 21.3 million shares, above average volume of 11 thousand, on the Nasdaq. The stock opened its trading at $3.9600 after closing Monday at $2.8500. The stock has traded between $2.5100 and $5.5500 in the past 52-week period.
The agreement will cover key Asian marketplaces, including Japan and China.
Under the terms of the agreement, Senju h...